Prescription Summary

Medications

1. Tab. DEPAKOTE 500 mg (Divalproex Sodium)

• Class: Anticonvulsant / Mood stabilizer
• Use here: First-line mood stabilizer for bipolar disorder - effective in acute mania and maintenance. Divalproex is a stable formulation of valproate that causes less GI irritation than valproic acid.
• Mechanism: Enhances GABA activity, inhibits sodium channels, reduces neuronal excitability.
• Key monitoring: LFTs, CBC (risk of thrombocytopenia), serum valproate levels (target 50-100 mcg/mL), weight gain, teratogenicity (neural tube defects - avoid in women of childbearing age if possible).

2. Tab. INTALITH 450 mg CR (Lithium Carbonate, Controlled Release)

• Class: Mood stabilizer (the prototype)
• Use here: Gold standard for bipolar disorder - effective for mania, depression, and suicide prevention. CR formulation reduces peak plasma fluctuations and GI side effects.
• Mechanism: Modulates inositol signaling, GSK-3 inhibition, neurotrophic effects (increases BDNF).
• Key monitoring: Serum lithium levels (therapeutic range 0.6-1.2 mEq/L for maintenance; narrow therapeutic index). Monitor renal function (creatinine), thyroid function, and watch for signs of toxicity (tremor, nausea, confusion, ataxia at levels >1.5 mEq/L).
• Note: The combination of lithium + valproate is a common augmentation strategy in treatment-resistant or severe bipolar disorder.

3. Tab. QSIZ 12.5 mg (Quetiapine)

• Class: Atypical (second-generation) antipsychotic
• Use here: FDA-approved for acute mania, bipolar depression, and maintenance in bipolar disorder. At low doses (12.5-25 mg), it is often used primarily as a sedative/sleep aid, given its strong H1-antihistamine activity at low doses. This dose is sub-antipsychotic.
• Mechanism: D2, 5-HT2A, H1, alpha-1 antagonism.
• Side effects: Sedation, weight gain, metabolic syndrome, QTc prolongation (monitor ECG).

4. Tab. RISDONE MT 1 mg (Risperidone MD - Mouth Dissolving)

• Class: Atypical antipsychotic
• Use here: Approved for acute mania and mixed episodes in bipolar disorder. The MD (mouth dissolving) formulation improves compliance. At 1 mg, this is a low dose - may be targeting residual psychotic symptoms or agitation.
• Mechanism: D2 and 5-HT2A antagonism.
• Side effects: EPS (more than other atypicals at higher doses), hyperprolactinemia, metabolic effects.

5. Tab. DAYVIGO 10 mg (Lemborexant)

• Class: Dual orexin receptor antagonist (DORA)
• Use here: FDA-approved for insomnia. Targeting the sleep disruption noted in the clinical notes ("skipped night"). Blocks orexin (hypocretin) receptors OX1R and OX2R, promoting sleep by dampening wake-promoting signals.
• Dosing: Available in 5 mg and 10 mg; 10 mg is the higher approved dose.
• Advantages over older sedatives: Does not cause rebound insomnia, minimal dependence risk, preserves sleep architecture better than benzodiazepines or Z-drugs.
• Side effects: Somnolence, next-morning impairment (caution with driving), sleep paralysis (rare).

6. Tab. ZONALTA 8 mg x 10 tabs (Endoxifen 8 mg)

• Class: Active metabolite of tamoxifen / Protein kinase C (PKC) inhibitor
• Use here: This is a notable and relatively newer addition. Endoxifen is the primary active metabolite of tamoxifen. Two RCTs have demonstrated that endoxifen is effective as an antimanic agent comparable to valproate in acute mania - this is through its PKC inhibition, not its estrogenic/anti-estrogenic mechanism. It has been studied as an adjunctive mood stabilizer in bipolar disorder, particularly in patients where other agents have limitations.
• Important: The 10-tablet supply suggests this may be used short-term (acute phase).
• Side effects: Nausea, hot flashes, hormonal effects (anti-estrogenic activity remains present).

Overall Clinical Picture